Alimera Sciences, Inc.

Alimera Sciences, Inc. operates as a pharmaceutical company that develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME); and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. The company was incorporated in 2003 and is based in Alpharetta, Georgia. As of September 16, 2024, Alimera Sciences, Inc. operates as a subsidiary of ANI Pharmaceuticals, Inc.